Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will help to understand the interaction between estrogen receptor-alpha (ER alpha)
and tumor suppressor protein p53 as well as impact on patient tumor gene expression in
response to the hormonal therapy Tamoxifen. This information may eventually help select the
appropriate therapy for future patients with similar cancer.
Phase:
N/A
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)